ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 579,17
-0,70%
Dow Jones
40 211,72
0,00%
DAX
18 504,68
-0,51%
Brent Oil
82,865
-1,75%
Bitcoin
63 798,26
-1,62%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Portola Pharmaceuticals Inc (PTLA)

  7. Portola Pharmaceuticals Inc (PTLA) Actualités

PTLA

Portola Pharmaceuticals (PTLA)

Portola Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:PTLA
DateHeureSourceTitreSymboleSociété
24/02/201414h38Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:PTLAPortola Pharmaceuticals Inc
24/02/201414h00GlobeNewswire Inc.Portola Pharmaceuticals to Present at the Cowen and Company 34th Annual Health Care ConferenceNASDAQ:PTLAPortola Pharmaceuticals Inc
20/02/201414h00GlobeNewswire Inc.Portola Pharmaceuticals to Announce Fourth Quarter and Year End 2013 Financial Results and Host Conference Call on Thursday, ...NASDAQ:PTLAPortola Pharmaceuticals Inc
14/02/201415h37Edgar (US Regulatory)Schedule 13gNASDAQ:PTLAPortola Pharmaceuticals Inc
12/02/201421h04Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:PTLAPortola Pharmaceuticals Inc
03/02/201414h00GlobeNewswire Inc.Portola Pharmaceuticals Enters Into Clinical Collaboration Agreement With Bayer and Janssen for Phase 3 Studies of Andexanet ...NASDAQ:PTLAPortola Pharmaceuticals Inc
13/01/201414h00GlobeNewswire Inc.Portola Pharmaceuticals Enters Second Clinical Collaboration Agreement With Bristol-Myers Squibb and Pfizer to Study Andexane...NASDAQ:PTLAPortola Pharmaceuticals Inc
06/01/201414h00GlobeNewswire Inc.Portola Pharmaceuticals Announces Webcast of Corporate Presentation on January 13, 2014NASDAQ:PTLAPortola Pharmaceuticals Inc
09/12/201317h00GlobeNewswire Inc.Portola Pharmaceuticals Announces New Phase 2 Results Confirming Immediate, Dose-Dependent and Well-Tolerated Reversal of Ant...NASDAQ:PTLAPortola Pharmaceuticals Inc
03/12/201314h00GlobeNewswire Inc.Portola Pharmaceuticals Announces Upcoming Data Presentations on Andexanet Alfa (PRT4445*) and PRT2070 at 55th American Socie...NASDAQ:PTLAPortola Pharmaceuticals Inc
25/11/201314h00GlobeNewswire Inc.Portola Pharmaceuticals Receives Breakthrough Therapy Designation From FDA for Andexanet Alfa (PRT4445*), Investigational Fac...NASDAQ:PTLAPortola Pharmaceuticals Inc
15/11/201314h12Dow Jones NewsFidelity Management & Research Co. 3Q 13F: Largest EliminationsNASDAQ:PTLAPortola Pharmaceuticals Inc
15/11/201314h12Dow Jones NewsFidelity Management & Research Co. 3Q 13F: Largest SalesNASDAQ:PTLAPortola Pharmaceuticals Inc
15/11/201314h12Dow Jones NewsFidelity Management & Research Co. 3Q 13F: -2-NASDAQ:PTLAPortola Pharmaceuticals Inc
15/11/201314h12Dow Jones NewsFidelity Management & Research Co. 3Q 13F: Largest PurchasesNASDAQ:PTLAPortola Pharmaceuticals Inc
11/11/201314h00GlobeNewswire Inc.Portola Pharmaceuticals Announces Additional Positive Phase 2 Proof-of-Concept Data for Andexanet Alfa (PRT4445*)NASDAQ:PTLAPortola Pharmaceuticals Inc
06/11/201323h24Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:PTLAPortola Pharmaceuticals Inc
05/11/201322h00GlobeNewswire Inc.Portola Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate UpdateNASDAQ:PTLAPortola Pharmaceuticals Inc
31/10/201313h00GlobeNewswire Inc.Portola Pharmaceuticals to Announce Third Quarter 2013 Financial Results and Host Conference Call on Tuesday, November 5, 201...NASDAQ:PTLAPortola Pharmaceuticals Inc
24/10/201322h00GlobeNewswire Inc.Portola Pharmaceuticals Announces Enrollment Has Begun in Phase 1/2 Study of PRT2070, an Oral Dual Syk/JAK Inhibitor for Gene...NASDAQ:PTLAPortola Pharmaceuticals Inc
17/10/201322h41Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(4) (424b4)NASDAQ:PTLAPortola Pharmaceuticals Inc
17/10/201314h32GlobeNewswire Inc.Portola Announces Pricing of Public Offering of Common StockNASDAQ:PTLAPortola Pharmaceuticals Inc
17/10/201312h01Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:PTLAPortola Pharmaceuticals Inc
16/10/201323h26Edgar (US Regulatory)Securities Registration Statement (s-1/a)NASDAQ:PTLAPortola Pharmaceuticals Inc
16/10/201312h56GlobeNewswire Inc.Portola Pharmaceuticals Announces Proposed Offering of Common StockNASDAQ:PTLAPortola Pharmaceuticals Inc
15/10/201323h05GlobeNewswire Inc.Portola Pharmaceuticals Announces Release of Lock-up Restriction for Common Stock Held by a Director of the CompanyNASDAQ:PTLAPortola Pharmaceuticals Inc
14/10/201323h05GlobeNewswire Inc.Portola Pharmaceuticals Announces First Phase 2 Results Demonstrating Extended Duration Infusion With Andexanet Alfa (PRT4445...NASDAQ:PTLAPortola Pharmaceuticals Inc
09/10/201314h00GlobeNewswire Inc.Portola Pharmaceuticals Announces Initiation of Phase 1/2 Clinical Study of PRT2070NASDAQ:PTLAPortola Pharmaceuticals Inc
07/10/201322h52Edgar (US Regulatory)Securities Registration Statement (s-1)NASDAQ:PTLAPortola Pharmaceuticals Inc
20/09/201312h00MarketwiredVital Therapies, Inc. Expands Board of DirectorsNASDAQ:PTLAPortola Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:PTLA

Dernières Valeurs Consultées

LSE
30GK
Bristol W.4q%
LSE
ESG
Eservglobal
LSE
CMU
Amundi Emu Esg
BOV
TRNT11
Fdo Invest Imobiliario T...
NYSE
LB
LandBridge
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés